Innovator: The Rise of Theragnostics

May 1, 2015
Innovator: The Rise of Theragnostics
AAA currently has 17 production and research and development facilities that manufacture both diagnostic and therapeutic molecular nuclear medicine products.

Gail Dutton

Advanced Accelerator Applications (AAA) is pioneering work in theragnostics—the blending of therapeutics and diagnostics capabilities into one drug for nuclear medicine applications.

“Theragnostics is a very straightforward proposition for physicians dealing with nuclear medicine,” says Stefano Buono, AAA’s CEO and founder. This approach attaches radioisotopes to therapeutic molecules to deliver therapeutics and imaging in one injection. “The isotopes don’t change the nature of the chemical entity, and they don’t change the ability for targeting,” he explains.

Traditionally, most radioactive compounds used in healthcare are active about 10 hours. AAA has produced more than 30,000 batches of such compounds for medical centers since spinning out of CERN in 2002. The company has expanded its work to include therapeutic compounds. “We can make therapeutic, radioactive compounds that have a three-day window,” Buono asserts.

Unlike traditional nuclear medicine approaches, which can’t treat metastatic disease, theragnostics is effective for tumors that are so widespread they can’t be treated with radiotherapy or surgery.

These new capabilities, Buono insists, have the potential to transform nuclear medicine from a niche therapy to “a pillar of medicine.”

For the rest of the story, click here.

×

Oops! Please type your email in the following format: [email protected]

You’re all set!
Thank you for subscribing to
Clinical OMICs Weekly
.